Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.36 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 5/20 | 0.36 |
| ▸ | SYK | P43405 | 4/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22122975 | 1.00 | F10 (0.41) | F10PTK6PTK2MAPKAPK5TTK | |
| SCHEMBL30171688 | 0.94 | TTK (0.40) | F10PTK6PTK2MAPKAPK5TTK | |
| SCHEMBL22123046 | 0.94 | TTK (0.40) | F10PTK6PTK2MAPKAPK5TTK | |
| SCHEMBL30385437 | 0.91 | TP53 (0.40) | PTK6PTK2SYK | |
| SCHEMBL22122899 | 0.91 | PTK2 (0.41) | F10PTK6PTK2MAPKAPK5TTK | |
| SCHEMBL30171847 | 0.90 | GSK3B (0.37) | PTK6PTK2TTKHTR4 | |
| SCHEMBL22122933 | 0.90 | GSK3B (0.37) | PTK6PTK2TTKHTR4 | |
| SCHEMBL22123264 | 0.89 | PTK2 (0.46) | PTK6PTK2MAPKAPK5TTKHTR4 | |
| SCHEMBL22123498 | 0.89 | PTK2 (0.36) | PTK6PTK2MAPKAPK5TTKSYK | |
| SCHEMBL22123023 | 0.88 | PTK6 (0.36) | PTK6PTK2MAPKAPK5TTKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | F10 2530/4885PTK6 2211/4885PTK2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.